The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.

Elosulfase alfa 24 month-like review

This 24 month-like review aimed to ensure that the listing of elosulfase alfa for the treatment of MPS IVA on the LSDP remains appropriate. It was considered by the Expert Panel at its October 2022 and February 2023 meetings.

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.